
Sign up to save your podcasts
Or


For nearly a century, U.S. cosmetic regulation remained largely unchanged. That era officially ended with the passage of the Modernization of Cosmetics Regulation Act (MoCRA), and now, the FDA is racing to catch up.
In Episode 83 of the Orange Pill Podcast, we unpack five major regulatory developments that signal a fundamental shift in how cosmetics are tested, labeled, and enforced in the United States.
Drawing from recent FDA actions and the Fall 2024 Unified Agenda, this episode explores:
• The FDA’s long-awaited move to mandate asbestos testing in talc products
We discuss what these shifts mean for brands, manufacturers, regulatory teams, and consumers, and why companies should already be preparing their quality systems, documentation, and compliance strategies.
This episode isn’t just about beauty. It’s about accountability, transparency, and the future of consumer protection.
By KGK ScienceFor nearly a century, U.S. cosmetic regulation remained largely unchanged. That era officially ended with the passage of the Modernization of Cosmetics Regulation Act (MoCRA), and now, the FDA is racing to catch up.
In Episode 83 of the Orange Pill Podcast, we unpack five major regulatory developments that signal a fundamental shift in how cosmetics are tested, labeled, and enforced in the United States.
Drawing from recent FDA actions and the Fall 2024 Unified Agenda, this episode explores:
• The FDA’s long-awaited move to mandate asbestos testing in talc products
We discuss what these shifts mean for brands, manufacturers, regulatory teams, and consumers, and why companies should already be preparing their quality systems, documentation, and compliance strategies.
This episode isn’t just about beauty. It’s about accountability, transparency, and the future of consumer protection.